Revolutionizing Precision Medicine with AI-Powered Platforms
Welcome to DeepTarget Biotherapeutics
DeepTarget Bio is a biotechnology company advancing therapeutics for fibrosis and cancer through disease-specific targets, differentiated MOAs, and innovative modalities. Our cutting-edge AI-powered platform propels end-to-end pipeline development with high efficiency and success rates, accelerating from groundbreaking discovery through clinical trials and into transformative therapies.
Our Unique Approach
Transformative Therapy for Fibrosis
Transformative Therapy for Fibrosis
Transformative Therapy for Fibrosis
- Specifically Target Pathogenic Fibrosis Drivers & Effectors
- Shift from Passive Fibrosis Suppression to Active Disease Reversal
- Organ-Agnostic Antifibrotic Platform
Cutting Edge Therapeutics Design
Transformative Therapy for Fibrosis
Transformative Therapy for Fibrosis
- BiME™: Bispecific Macrophage Engager
- TSI™: Bi-/Tri-Specific Immune Modulator
- ICE™: Next-Generation Immune Cell Engager
- In Vivo Cell Therapy
Proprietary Agentic Bio AI System
Transformative Therapy for Fibrosis
Proprietary Agentic Bio AI System
The DeepTarget AI system, DTB.AI™, is a Large Reasoning Model (LRM), combining Inverse Reinforcement Learning and Reinforcement Learning with a human-in-the-loop framework, leveraging domain expertise feedback from our experienced drug developers.
Our Mission
Deliver differentiated therapies that address the underlying drivers of diseases with high unmet medical need
Our Expertise
Our leadership team comprises seasoned pharmaceutical experts from Merck, Amgen, Regeneron, AstraZeneca, Teva, and Sanofi, with a proven track record in end-to-end drug development. Collectively, they have contributed to over 60+ INDs, 10+ BLAs/MAAs.
Leadership Team
Zhimei Du, MD, PhD Chief Executive Officer
Bill Fanslow, PhD Chief Scientific Officer
Bill Fanslow, PhD Chief Scientific Officer
Dr. Zhimei Du is a seasoned biotech executive with more than 20 years of leadership experience spanning corporate strategy, business development, R&D, portfolio management, and drug development from discovery through commercialization. She has built and led global organizations, defined corporate and portfolio strategies, directed investm
Dr. Zhimei Du is a seasoned biotech executive with more than 20 years of leadership experience spanning corporate strategy, business development, R&D, portfolio management, and drug development from discovery through commercialization. She has built and led global organizations, defined corporate and portfolio strategies, directed investments in emerging technologies, and managed organizational structure, budgets, and resources to drive growth and execution.
Dr. Du has extensive experience across the full business development lifecycle, including search & evaluation, due diligence, licensing, clinical collaborations, and strategic transactions. She has negotiated and closed multiple partnerships with significant upfront economics and established broad collaborations across biopharma, academia, and emerging biotechnology companies to expand pipelines, platforms, and strategic capabilities.
Prior to founding DeepTarget Bio, Dr. Du served as Chief Scientific Officer at BlueSphere Bio, Vice President at Atara Biotherapeutics and Landmark Bio, and Executive Director and Global Head of Process Cell Sciences at Merck & Co., where she built and led global, multi-site organizations supporting biologics and cell/gene therapy development and helped shape investments in emerging therapeutic technologies. Her industry experience also includes scientific and leadership roles at Amgen and Regeneron.
Across her career, she has contributed to the advancement of 25 INDs, 3 BLAs, and 1 MAA across biologics, cell and gene therapies, and other advanced therapeutic modalities. She has also initiated and led industry-wide consortia and multidisciplinary external collaborations at the intersection of emerging science, technology, and therapeutic development.
Bill Fanslow, PhD Chief Scientific Officer
Bill Fanslow, PhD Chief Scientific Officer
Bill Fanslow, PhD Chief Scientific Officer
Dr. Bill Fanslow brings more than 30 years of biotechnology leadership in therapeutic discovery and development, with deep expertise in fibrosis, oncology, immuno-oncology, and biologics. As Chief Scientific Officer of DeepTarget Bio, he leads scientific strategy, target and therapeutic discovery, translational development, and advancemen
Dr. Bill Fanslow brings more than 30 years of biotechnology leadership in therapeutic discovery and development, with deep expertise in fibrosis, oncology, immuno-oncology, and biologics. As Chief Scientific Officer of DeepTarget Bio, he leads scientific strategy, target and therapeutic discovery, translational development, and advancement of the company’s pipeline toward the clinic.
Prior to joining DeepTarget Bio, Dr. Fanslow served as Senior Vice President of Therapeutic Drug Discovery and Development at Fibrocor, where he led antibody discovery and development against profibrotic targets and advanced FIB918 into IND-enabling development. He previously co-founded Sound Biologics and served as EVP of R&D/CSO, advancing its MabPair bispecific antibody platform and lead oncology programs into clinical development. Earlier, during 12 years at Amgen, he rose to Executive Director and led therapeutic innovation programs spanning monoclonal antibodies, bispecifics, ADCs, immuno-oncology, and translational platforms. He began his industry career at Immunex.
Across his career, Dr. Fanslow has contributed to 10 INDs, 6 clinical programs, and 1 BLA. He is a named inventor on 54+ issued U.S. patents and an author or co-author of 110+ peer-reviewed publications. He received his Ph.D. in Biochemistry and Molecular Biology from Rice University.
Douglas L. Mayers, MD, Chief Medical Officer
Bill Fanslow, PhD Chief Scientific Officer
Douglas L. Mayers, MD, Chief Medical Officer
Dr. Douglas Mayers is an accomplished physician-executive with more than 30 years of experience in clinical development, medical strategy, and drug development spanning biotechnology, global pharmaceutical companies, academia, and government. He has led global clinical programs from early development through registration across infectious
Dr. Douglas Mayers is an accomplished physician-executive with more than 30 years of experience in clinical development, medical strategy, and drug development spanning biotechnology, global pharmaceutical companies, academia, and government. He has led global clinical programs from early development through registration across infectious diseases and other serious illnesses, with extensive experience in clinical strategy, drug safety, regulatory interactions, and development-stage portfolio leadership.
Dr. Mayers previously served as Executive Vice President and Chief Medical Officer of Idenix Pharmaceuticals, International Head and Vice President of Virology at Boehringer Ingelheim, Chief Medical Officer of Cocrystal Pharma, and Co-Founder and Chief Medical Officer of Antios Therapeutics. His career includes oversight of numerous global clinical development programs, including approved antiviral therapies and multiple investigational drug candidates. He has also served as a Principal Investigator at USAMRIID and led NIH-funded clinical trials programs.
Dr. Mayers has served as a consultant to the FDA and on numerous federal and NIH committees, study sections, and advisory groups. He is a Fellow of the American College of Physicians and the Infectious Diseases Society of America and received the Jay P. Sanford Award for lifetime professional achievement. He earned his MD from the University of Pennsylvania and completed his Internal Medicine training at the University of Virginia.
Nuno Coelho, PhD Head of Discovery
Bill Fanslow, PhD Chief Scientific Officer
Douglas L. Mayers, MD, Chief Medical Officer
Dr. Nuno M. Coelho is a translational scientist with more than 15 years of experience in fibrosis biology, disease mechanisms, target discovery, and preclinical development. As Head of Discovery at DeepTarget Bio, he leads target identification and validation, mechanistic studies, preclinical model development, and translational strategy
Dr. Nuno M. Coelho is a translational scientist with more than 15 years of experience in fibrosis biology, disease mechanisms, target discovery, and preclinical development. As Head of Discovery at DeepTarget Bio, he leads target identification and validation, mechanistic studies, preclinical model development, and translational strategy to advance novel therapeutic programs from discovery toward IND-enabling development.
Dr. Coelho has extensive experience integrating advanced in vitro, ex vivo, and in vivo models—including 3D organoids and spheroids—to establish human-relevant evidence for target validation, pharmacology, biomarker development, PK/PD strategy, and dose selection. His scientific work has focused on ECM remodeling, mechanotransduction, fibrosis-relevant signaling pathways, and the discovery and validation of novel therapeutic targets in fibrosis and oncology.
He has led cross-disciplinary collaborations spanning pharmacology, toxicology, DMPK, translational medicine, and clinical development, and has contributed to IND-enabling and regulatory documentation. Dr. Coelho has authored 20+ peer-reviewed publications and is a co-inventor on antibody intellectual property in fibrosis and cancer. He received his Ph.D. in Biomedical Engineering from the Universitat Politècnica de Catalunya.